

Closed and open scaffolds for bone regeneration

João F. Mano^{1,2}

¹ 3B's Research Group - Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine. AvePark, Zona Industrial da Gandra, S. Cláudio do Barco, 4806-909 Caldas das Taipas, Guimarães, Portugal.

² ICVS / 3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.



Repair of damaged/diseased tissues and organs

failure/loss/damaging of tissues and organs

- Chronic diseases / aged-linked degeneration
- Trauma / accidents
- congenital deformity

organ transplantation



replacement strategies (biomaterials/ artif. organs)



pharmaceuticals



tissue transplantation



need for developing:


- novel strategies for restoring the structure and function of tissues and organs.
- methods of curing previously untreatable injuries and diseases.

• • .3B's:
A logo featuring three small black dots arranged horizontally above a 3x5 grid of 15 small, evenly spaced circles.


ICVS/3B's
Associate
Laboratory
University of Minho



Tissue Engineering



peripheral nervous tissue






Volume 141, 15 February 2015

ISSN 0167-577X

materials letters

Featured Letter:
Designing Biomaterials for Tissue Engineering Based
on the Deconstruction of the Native Cellular Environment



An interdisciplinary journal devoted to the rapid publication of short communications on the science, applications and processing of materials

Editor-in-Chief: Aldo R. Boccaccini

J.F. Mano, *Mater. Lett.* '15
(featured letter)




ICVS/3B's
Associate
Laboratory




Natural based polymers

polysaccharides




proteins

silk fibroin




collagen



fibronectin


polyesters




poly(hydroxybutyrate)

3D supports for cells in tissue engineering

OPEN




porous scaffolds



solid supportive particles
• .3B's:

CLOSED




liquified/elastic environment

- cells+biomaterials+soluble factors may be retained in the same volume.
- self-regulated strategies.
- Use of non-autologous cells.
- Injectable systems.



Rapid Prototyping Technique



Human Body




X-Ray



CAD software



Scaffold with tissue



Cell culture



RP machine



3D Scaffold


• • .3B's:

ICVS/3B's
Associate
Laboratory
University of Minho





Rapid Prototyping Technique: control of morphology


Standard scaffold morphologies with porosities ranging between 55 and 85 %.




Multiscale Features/Properties for 3D Constructs Design



Layer-by-layer methodology using polyelectrolytes solutions



Platelets



EDMOND ALEXANDER, Shannon Associates LLC

Growth factors

FGF
VEGF
PDGF
TGF β
BMP-2, BMP-4,...
IGF-1
...

Adhesion proteins

Fibronectin
Vitronectin
Trombospondin
Vit-D binding protein

Antigen receptors


PECAM-1
P-selectin

Hemostatic factors

Fibrinogen
Protein S

Events trigger platelets activation and the release of contents:
Vascular disruption and/or tissue injury

- cost-effective autologous source of multiple growth factors.
- Involved in vivo in very important physiological functions.



Chemokines




IL-1 β
IL-8
PF-4
SDF-1 α

Others



• • .3B's:




multilayers containing PL



Incorporating human platelet lysates in the multilayers



SAMPLES



Platelets:

- Events trigger platelets activation and the release of contents: Vascular disruption and/or tissue injury.
- Cost-effective autologous source of multiple growth factors



Hypothesis:


- PLs could be included in multilayers as a structural component and its presence could have beneficial biological implications.

• • .3B's:

S.M. Oliveira+, ACS Biomater.Sci.&Eng., '15

ICVS/3B's
Associate Laboratory
University of Minho






Hierarchical scaffolds containing PLs: osteogenic potential

BIOMINERALIZATION

+Dex
-Dex




Cell studies

hASCs P1: 0.12×10^6 /scaffold

a mem 4D


+ 28 days: L-AA + β Gly, with and without Dexamethasone (Dex)



Hierarchical scaffolds containing PLs: osteogenic potential

+Dex

IMMUNODETECTION OF OSTEOCALCIN



-Dex




Green – Osteocalcin; Red – Alizarin Red S; Blue - Nuclei


Relevant properties influencing the behaviour of encapsulated cells

L. Gasperini, J.F. Mano, R.L. Reis, *J.R.Soc.Interface* '14

Bulk nature: water content, chemical composition, crosslinking density, stimuli responsiveness, mechanical properties




Feeding the cells






Bioinstructive particles

Concept: polymeric microparticles that are able to target specific cells through antibody–antigen interactions, while simultaneously allowing cell expansion of target cells.




Particles with specific interactions with stem cells and endothelial cells

- CD90 is a cell surface glycoprotein that has been identified in stem cells.
- CD31 is found on the surface of endothelial cells.




ASCs adhere on CD90 particles.
HUVECs adhere on CD31 particles.


Injectability and *in situ* scaffold formation



Encapsulation of cells in microparticles-in-capsules




Preparation of liquified capsules




hierarchical (liquified) capsules

<nm>




(a)



<μm>

(a) PLLA particles -
diameter $45.6 \pm 13.5 \mu\text{m}$

(b)



<mm>

(b) capsules - diameter $1.8 \pm 0.1 \text{ mm}$.




C.R. Correia+, *Soft Matter* '13
C.R. Correia+, *Biomacromolecules* '13

ICVS/3B's
Associate Laboratory
University of Minho




Liquified capsules: Cell adhesion and proliferation studies




DAPI-phalloidin fluorescence assay

CONTROL: alginate particles without LbL nor EDTA treatment;
ALG: alginate particles after 6 bilayers and EDTA treatment (ALG capsules);
PLLA: alginate particles containing collagen I coated PLLA microparticles after 6 bilayers and EDTA treatment (PLLA capsules).

DNA quantification assay




Soft Matter




C.R. Correia+, *Soft Matter* '13
C.R. Correia+, *Biomacromolecules* '13

Osteogenic (bone forming) Capsules

Co-cultures to explore the crosstalk existing between vascular cells and stem cells.




Isolated cells phenotype & co-encapsulation analysis





in vitro

MONO capsules




CO capsules



Alizarin red




Osteopontin

DAPI Osteopontin



50µm



Chondrogenic Capsules



• .3B's:

C.R. Correia+, *Adv. Health. Mater.* '16


magnetite-nanoparticles incorporated into
the multilayered membrane



Encapsulated hASCs, using PLLA with two coatings:


- Col-II/TGF- β 3 (cultured in TGF- β 3 deprived medium);
- Col-II coating (cultured in medium containing TGF- β 3).

C.R. Correia+, *Adv. Health. Mater.* '16




Exogenous TGF- β 3

nanofibers in the newly deposited ECM
resembles the collagen fibrils of native cartilage




Chondrogenic Capsules: histology



The presence of the major constituent of cartilage, collagen II, was detected by immunocytochemistry and safranin-O and alcian blue stainings revealed a basophilic ECM deposition (rich in glyco and proteoglycans), which is characteristic of neocartilage

Chondrogenic Capsules: RT-PCR



The production of glycosaminoglycans and the expression of cartilage-relevant markers (collagen II, Sox9, aggrecan, and COMP) increased up to 28 days, while hypertrophic (collagen X) and fibrotic (collagen I) markers were downregulated.

Acknowledgements:

Students involved in the projects

International collaborators

Financial support:

-FCT (NanoBioactive, SmartCarbo, ProteoLight, SupraRelax, Matryoshkas)

-FP6 / FP7



- ELASTISLET (NMP)
- CHEM2NATURE (TWINNING)
- ATLAS (ERC-AdG)

